Ser780

Site Information
FDNIDNLsPKASHRS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2023357

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 )
Disease tissue studied:	breast cancer ( 5 , 8 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 , 5 ) , cervical cancer ( 13 ) , cervical adenocarcinoma ( 13 ) , leukemia ( 15 ) , chronic myelogenous leukemia ( 15 ) , lung cancer ( 8 ) , non-small cell lung cancer ( 8 ) , ovarian cancer ( 5 )
Relevant cell line - cell type - tissue:	breast ( 2 , 5 ) , BT-20 (breast cell) ( 8 ) , BT-549 (breast cell) ( 8 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1937 (breast cell) ( 8 ) , HCC2279 (pulmonary) ( 8 ) , HeLa (cervical) ( 4 , 10 , 11 , 14 ) , HeLa S3 (cervical) ( 13 ) , Jurkat (T lymphocyte) ( 7 , 12 ) , K562 (erythroid) ( 15 ) , liver ( 6 ) , MCF-7 (breast cell) ( 8 ) , MDA-MB-231 (breast cell) ( 8 ) , MDA-MB-468 (breast cell) ( 8 ) , NCI-H1395 (pulmonary) ( 8 ) , NCI-H157 (pulmonary) ( 8 ) , NCI-H1666 (pulmonary) ( 8 ) , NCI-H2030 (pulmonary) ( 8 ) , NCI-H2172 (pulmonary) ( 8 ) , NCI-H520 (squamous) ( 8 ) , ovary ( 5 ) , PC9 (pulmonary) ( 8 ) , Vero E6-S ('epithelial, kidney') ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 13 ) , Y27632 ( 10 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
7	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
8	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
9	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
10	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
11	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
12	Possemato A (2010) CST Curation Set: 9793; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
13	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
14	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
15	Stokes M (2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info